JP2019506842A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019506842A5 JP2019506842A5 JP2018528604A JP2018528604A JP2019506842A5 JP 2019506842 A5 JP2019506842 A5 JP 2019506842A5 JP 2018528604 A JP2018528604 A JP 2018528604A JP 2018528604 A JP2018528604 A JP 2018528604A JP 2019506842 A5 JP2019506842 A5 JP 2019506842A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- chain variable
- variable region
- amino acid
- heavy chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 414
- 239000000427 antigen Substances 0.000 claims description 147
- 102000036639 antigens Human genes 0.000 claims description 147
- 108091007433 antigens Proteins 0.000 claims description 147
- 239000012634 fragment Substances 0.000 claims description 119
- 206010028980 Neoplasm Diseases 0.000 claims description 30
- 201000011510 cancer Diseases 0.000 claims description 27
- 102100031507 Fc receptor-like protein 5 Human genes 0.000 claims description 21
- 101710120217 Fc receptor-like protein 5 Proteins 0.000 claims description 20
- 239000000203 mixture Substances 0.000 claims description 16
- 210000004027 cell Anatomy 0.000 claims description 15
- 208000034578 Multiple myelomas Diseases 0.000 claims description 14
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 12
- 229940127121 immunoconjugate Drugs 0.000 claims description 11
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims description 7
- 102000039446 nucleic acids Human genes 0.000 claims description 7
- 108020004707 nucleic acids Proteins 0.000 claims description 7
- 150000007523 nucleic acids Chemical class 0.000 claims description 7
- 229940124597 therapeutic agent Drugs 0.000 claims description 7
- 101000846908 Homo sapiens Fc receptor-like protein 5 Proteins 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 6
- 239000013604 expression vector Substances 0.000 claims description 4
- 101710112752 Cytotoxin Proteins 0.000 claims description 3
- 231100000599 cytotoxic agent Toxicity 0.000 claims description 3
- 239000002619 cytotoxin Substances 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 3
- 210000002865 immune cell Anatomy 0.000 claims description 2
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 claims 318
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 6
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 6
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 6
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 3
- 208000011691 Burkitt lymphomas Diseases 0.000 claims 3
- 208000017604 Hodgkin disease Diseases 0.000 claims 3
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 3
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 3
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims 3
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 3
- 201000009277 hairy cell leukemia Diseases 0.000 claims 3
- 201000000564 macroglobulinemia Diseases 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000001093 anti-cancer Effects 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 description 160
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 description 24
- 238000012986 modification Methods 0.000 description 8
- 230000004048 modification Effects 0.000 description 8
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 229920001184 polypeptide Polymers 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- HVLSXIKZNLPZJJ-TXZCQADKSA-N HA peptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 HVLSXIKZNLPZJJ-TXZCQADKSA-N 0.000 description 1
- 208000016025 Waldenstroem macroglobulinemia Diseases 0.000 description 1
- 230000005880 cancer cell killing Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022000137A JP2022033256A (ja) | 2015-12-04 | 2022-01-04 | Ｆｃ受容体様５を標的とする抗体および使用方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562263586P | 2015-12-04 | 2015-12-04 | |
| US62/263,586 | 2015-12-04 | ||
| PCT/US2016/064550 WO2017096120A1 (en) | 2015-12-04 | 2016-12-02 | Antibodies targeting fc receptor-like 5 and methods of use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022000137A Division JP2022033256A (ja) | 2015-12-04 | 2022-01-04 | Ｆｃ受容体様５を標的とする抗体および使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019506842A JP2019506842A (ja) | 2019-03-14 |
| JP2019506842A5 true JP2019506842A5 (enExample) | 2020-01-16 |
| JP7267009B2 JP7267009B2 (ja) | 2023-05-01 |
Family
ID=58797867
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018528604A Active JP7267009B2 (ja) | 2015-12-04 | 2016-12-02 | Ｆｃ受容体様５を標的とする抗体および使用方法 |
| JP2022000137A Pending JP2022033256A (ja) | 2015-12-04 | 2022-01-04 | Ｆｃ受容体様５を標的とする抗体および使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022000137A Pending JP2022033256A (ja) | 2015-12-04 | 2022-01-04 | Ｆｃ受容体様５を標的とする抗体および使用方法 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US10913796B2 (enExample) |
| EP (1) | EP3383913A4 (enExample) |
| JP (2) | JP7267009B2 (enExample) |
| KR (1) | KR20180089497A (enExample) |
| CN (2) | CN109071654B (enExample) |
| AU (2) | AU2016362402A1 (enExample) |
| BR (1) | BR112018011336A2 (enExample) |
| CA (1) | CA3007115A1 (enExample) |
| IL (2) | IL259747B (enExample) |
| MX (1) | MX2018006787A (enExample) |
| MY (1) | MY197441A (enExample) |
| NZ (1) | NZ743124A (enExample) |
| PH (1) | PH12018501177B1 (enExample) |
| SA (1) | SA518391722B1 (enExample) |
| SG (2) | SG10202005268WA (enExample) |
| WO (1) | WO2017096120A1 (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS62870B1 (sr) | 2014-12-05 | 2022-02-28 | Memorial Sloan Kettering Cancer Center | Himerni antigenski receptori sa ciljanim delovanjem na receptore spregnute sa g-proteinom i njihove upotrebe |
| MX395028B (es) | 2014-12-05 | 2025-03-24 | Memorial Sloan Kettering Cancer Center | Receptores de antigeno quimerico dirigidos al receptor fc 5 similar y sus usos. |
| HK1254803A1 (zh) * | 2015-06-23 | 2019-07-26 | Memorial Sloan Kettering Cancer Center | 新型pd -1的免疫调节剂 |
| AU2016342041B2 (en) | 2015-10-23 | 2021-12-02 | Eureka Therapeutics, Inc. | Antibody/T-cell receptor chimeric constructs and uses thereof |
| JP7267009B2 (ja) | 2015-12-04 | 2023-05-01 | メモリアル スローン ケタリング キャンサー センター | Ｆｃ受容体様５を標的とする抗体および使用方法 |
| WO2018200585A1 (en) | 2017-04-26 | 2018-11-01 | Eureka Therapeutics, Inc. | Cells expressing chimeric antigen receptors and secondary effectors and uses thereof |
| TW201925782A (zh) | 2017-11-30 | 2019-07-01 | 瑞士商諾華公司 | 靶向bcma之嵌合抗原受體及其用途 |
| SG11202003893UA (en) * | 2017-12-29 | 2020-05-28 | Ap Biosciences Inc | Monospecific and bispecific proteins with immune checkpoint regulation for cancer therapy |
| TWI848951B (zh) | 2018-06-01 | 2024-07-21 | 瑞士商諾華公司 | 針對ｂｃｍａ之結合分子及其用途 |
| JP6761889B1 (ja) * | 2019-11-11 | 2020-09-30 | 株式会社Ｇｓｐエンタープライズ | 抗ヒトＣｒｉｐｔｏ−１抗体 |
| TWI789711B (zh) * | 2020-02-24 | 2023-01-11 | 中國科學院微生物研究所 | 新型冠狀病毒的人源單克隆抗體及其應用 |
| KR20230090367A (ko) | 2020-11-04 | 2023-06-21 | 주노 쎄러퓨티크스 인코퍼레이티드 | 변형된 불변 cd3 이뮤노글로불린 슈퍼패밀리 쇄 유전자좌로부터 키메라 수용체를 발현하는 세포 및 관련 폴리뉴클레오티드 및 방법 |
| AU2021373366A1 (en) | 2020-11-06 | 2023-06-01 | Novartis Ag | Cd19 binding molecules and uses thereof |
| TW202241497A (zh) | 2021-01-05 | 2022-11-01 | 美商伊米若梅有限公司 | 針對SARS-CoV-2棘蛋白之抗體雞尾酒療法 |
| US20240108654A1 (en) | 2021-03-03 | 2024-04-04 | Juno Therapeutics, Inc. | Combination of a t cell therapy and a dgk inhibitor |
| CN117916256A (zh) | 2021-05-06 | 2024-04-19 | 朱诺治疗学有限公司 | 用于刺激和转导t细胞的方法 |
| JP2024523316A (ja) * | 2021-06-18 | 2024-06-28 | オートラス リミテッド | Ｃａｒ ｔ細胞における、および疾患の処置のための抗ｃｄ３０７ｅ単一ドメイン抗体、その使用 |
| US20250297282A1 (en) | 2022-05-05 | 2025-09-25 | Juno Therapeutics Gmbh | Viral-binding protein and related reagents, articles, and methods of use |
| CA3259982A1 (en) | 2022-06-30 | 2024-01-04 | Indapta Therapeutics Inc | COMBINATION OF MODIFIED NATURAL KILLER (NK) CELLS AND ANTIBODY THERAPY AND ASSOCIATED METHODS |
| WO2024047558A2 (en) * | 2022-08-31 | 2024-03-07 | Immuneel Therapeutics Private Limited | Antigen-binding proteins and chimeric antigen receptors specific for domain 9 of human cd307e |
| JP2025531850A (ja) | 2022-09-08 | 2025-09-25 | ジュノー セラピューティクス インコーポレイテッド | Ｔ細胞療法および継続的または間欠的ｄｇｋ阻害剤投薬の組合せ |
| WO2024100604A1 (en) | 2022-11-09 | 2024-05-16 | Juno Therapeutics Gmbh | Methods for manufacturing engineered immune cells |
| WO2024102948A1 (en) * | 2022-11-11 | 2024-05-16 | Celgene Corporation | Fc receptor-homolog 5 (fcrh5) specific binding molecules and bispecific t-cell engaging antibodies including same and related methods |
| EP4658675A1 (en) | 2023-02-03 | 2025-12-10 | C3S2 GmbH | Methods for non-viral manufacturing of engineered immune cells |
| WO2024218650A1 (en) * | 2023-04-19 | 2024-10-24 | Pfizer Inc. | Lilrb1 and lilrb2 antibodies and methods of use thereof |
| US20250127728A1 (en) | 2023-10-05 | 2025-04-24 | Capstan Therapeutics, Inc. | Constrained Ionizable Cationic Lipids and Lipid Nanoparticles |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| WO2025096878A1 (en) | 2023-11-02 | 2025-05-08 | Capstan Therapeutics, Inc. | Rna for in vivo transfection with increased expression |
| WO2025129201A1 (en) | 2023-12-15 | 2025-06-19 | Capstan Therapeutics, Inc. | Humanized anti-cd8 antibodies and uses thereof |
| US20250302763A1 (en) | 2024-02-22 | 2025-10-02 | Capstan Therapeutics, Inc. | Immune engineering amplification |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| JPS6412935A (en) | 1987-07-02 | 1989-01-17 | Mitsubishi Electric Corp | Constant-speed travel device for vehicle |
| US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
| SK281964B6 (sk) | 1993-09-03 | 2001-09-11 | Chugai Seiyaku Kabushiki Kaisha | Monoklonálna protilátka schopná vyvolať apoptózu myeloidných buniek, jej fragmenty a hybridóm |
| EP1232392B2 (de) * | 1999-10-12 | 2014-04-02 | Oxoid (Ely) Limited | Verbessertes verfahren zum nachweis von säure-resistenten bakterien der gattung helicobacter im stuhl |
| US6436703B1 (en) | 2000-03-31 | 2002-08-20 | Hyseq, Inc. | Nucleic acids and polypeptides |
| EP2275449B1 (en) * | 2000-06-16 | 2016-09-28 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to BLyS |
| US20090257994A1 (en) | 2001-04-30 | 2009-10-15 | City Of Hope | Chimeric immunoreceptor useful in treating human cancers |
| CA2476625A1 (en) * | 2002-02-20 | 2003-08-28 | Dyax Corp. | Mhc-peptide complex binding ligands |
| US7446190B2 (en) | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
| US7435596B2 (en) | 2004-11-04 | 2008-10-14 | St. Jude Children's Research Hospital, Inc. | Modified cell line and method for expansion of NK cell |
| ES2579805T3 (es) | 2004-09-23 | 2016-08-16 | Genentech, Inc. | Anticuerpos y conjugados modificados por ingeniería genética con cisteína |
| WO2006039238A2 (en) * | 2004-09-30 | 2006-04-13 | The Goverment Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Irta2 antibodies and methods of use |
| KR20070115881A (ko) | 2005-01-12 | 2007-12-06 | 메다렉스, 인코포레이티드 | 아이아르티에이-2 항체 및 그의 용도 |
| PT2856876T (pt) | 2007-03-30 | 2018-03-28 | Memorial Sloan Kettering Cancer Center | Expressão constitutiva de ligantes co-estimulatórios em linfócitos t adotivamente transferidos |
| EP2065398A1 (en) * | 2007-11-29 | 2009-06-03 | Cytos Biotechnology AG | Human monoclonal nicotine specific antibodies |
| RU2583270C2 (ru) * | 2009-04-01 | 2016-05-10 | Дженентек, Инк. | АНТИТЕЛА К FcRH5, ИХ ИММУНОКОНЪЮГАТЫ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ |
| SG174992A1 (en) | 2009-04-01 | 2011-11-28 | Genentech Inc | Anti-fcrh5 antibodies and immunoconjugates and methods of use |
| ES2911246T3 (es) | 2009-11-03 | 2022-05-18 | Hope City | Receptor del factor de crecimiento epidérmico truncado (EGFRT) para selección de células T transducidas |
| WO2014087010A1 (en) | 2012-12-07 | 2014-06-12 | Ablynx N.V. | IMPROVED POLYPEPTIDES DIRECTED AGAINST IgE |
| TWI635098B (zh) | 2013-02-01 | 2018-09-11 | 再生元醫藥公司 | 含嵌合恆定區之抗體 |
| KR20210108497A (ko) | 2013-02-26 | 2021-09-02 | 메모리얼 슬로안 케터링 캔서 센터 | 면역치료용 조성물 및 방법 |
| DK3004337T3 (da) | 2013-05-29 | 2017-11-13 | Cellectis | Fremgangsmåde til konstruktion af T-celler til immunoterapi ved brug af RNA-guidet Cas nuklease-system |
| TWI725931B (zh) * | 2013-06-24 | 2021-05-01 | 美商建南德克公司 | 抗ｆｃｒｈ５抗體 |
| WO2015142675A2 (en) | 2014-03-15 | 2015-09-24 | Novartis Ag | Treatment of cancer using chimeric antigen receptor |
| MX395028B (es) | 2014-12-05 | 2025-03-24 | Memorial Sloan Kettering Cancer Center | Receptores de antigeno quimerico dirigidos al receptor fc 5 similar y sus usos. |
| JP7267009B2 (ja) | 2015-12-04 | 2023-05-01 | メモリアル スローン ケタリング キャンサー センター | Ｆｃ受容体様５を標的とする抗体および使用方法 |
-
2016
- 2016-12-02 JP JP2018528604A patent/JP7267009B2/ja active Active
- 2016-12-02 WO PCT/US2016/064550 patent/WO2017096120A1/en not_active Ceased
- 2016-12-02 AU AU2016362402A patent/AU2016362402A1/en not_active Abandoned
- 2016-12-02 EP EP16871553.0A patent/EP3383913A4/en active Pending
- 2016-12-02 NZ NZ743124A patent/NZ743124A/en not_active IP Right Cessation
- 2016-12-02 MY MYPI2018000851A patent/MY197441A/en unknown
- 2016-12-02 CN CN201680081027.5A patent/CN109071654B/zh active Active
- 2016-12-02 SG SG10202005268WA patent/SG10202005268WA/en unknown
- 2016-12-02 IL IL259747A patent/IL259747B/en unknown
- 2016-12-02 IL IL295295A patent/IL295295A/en unknown
- 2016-12-02 CA CA3007115A patent/CA3007115A1/en active Pending
- 2016-12-02 KR KR1020187019114A patent/KR20180089497A/ko not_active Withdrawn
- 2016-12-02 MX MX2018006787A patent/MX2018006787A/es unknown
- 2016-12-02 PH PH1/2018/501177A patent/PH12018501177B1/en unknown
- 2016-12-02 CN CN202211132436.7A patent/CN116063508A/zh active Pending
- 2016-12-02 SG SG11201804656PA patent/SG11201804656PA/en unknown
- 2016-12-02 BR BR112018011336-0A patent/BR112018011336A2/pt not_active IP Right Cessation
-
2018
- 2018-06-03 SA SA518391722A patent/SA518391722B1/ar unknown
- 2018-06-04 US US15/997,155 patent/US10913796B2/en active Active
-
2021
- 2021-01-07 US US17/143,833 patent/US20210388081A1/en active Pending
-
2022
- 2022-01-04 JP JP2022000137A patent/JP2022033256A/ja active Pending
-
2023
- 2023-12-14 AU AU2023282276A patent/AU2023282276A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019506842A5 (enExample) | ||
| CN112969476B (zh) | 多特异性蛋白分子 | |
| KR20180089497A (ko) | Fc 수용체-유사 5를 표적화하는 항체 및 사용 방법 | |
| JP2017523786A5 (enExample) | ||
| WO2020114478A1 (zh) | Cd3抗体及其药物用途 | |
| JP2017530722A5 (enExample) | ||
| JP2018500014A5 (enExample) | ||
| US9725519B2 (en) | Antibody against transporter and use thereof | |
| AU2020298324A1 (en) | Anti-TIGIT antibodies | |
| JP2018504890A5 (enExample) | ||
| JP2012513214A5 (enExample) | ||
| JP2011207882A5 (enExample) | ||
| WO2020238926A1 (en) | Anti-b7-h3 antibodies | |
| CN113583116A (zh) | 针对SARS-CoV-1或SARS-CoV-2的抗体及其用途 | |
| CN113631582A (zh) | 一种融合蛋白及其用途 | |
| JP2018514193A5 (enExample) | ||
| JPWO2020011966A5 (enExample) | ||
| KR20220160670A (ko) | 항 pd-l1 및 pd-l2 항체 및 이의 유도체 및 용도 | |
| JPWO2022094299A5 (enExample) | ||
| JPWO2022114163A5 (enExample) | ||
| CN116284407A (zh) | 一种抗gucy2c抗体或其抗原结合片段及其用途 | |
| EP4168450A2 (en) | Cd38 antibodies for the treatment of human diseases | |
| JPWO2020041520A5 (enExample) | ||
| US20190389960A1 (en) | Compositions and methods for c1q targeted therapy | |
| JP7108956B2 (ja) | 抗ｃｌｄｎ－５抗体、及びその抗体を含有する医薬 |